B. Yip

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

B. Gazzard, C. Leen, B. Yip, 2017, HIV medicine.

Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.

P. Harrigan, B. Yip, R. Hogg, 2015, International journal of epidemiology.

Limited Evolution of Inferred HIV-1 Tropism while Viremia Is Undetectable during Standard HAART Therapy

P. Harrigan, B. Yip, D. Knapp, 2014, PloS one.

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression

Ross J. Harris, J. Sterne, A. Mocroft, 2009, Journal of acquired immune deficiency syndromes.

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μl

P. Harrigan, B. Yip, R. Hogg, 2006, AIDS.

Depressive symptoms decline among persons on HIV protease inhibitors.

B. Yip, R. Hogg, J. Montaner, 2000 .

Trends in AIDS incidence and AIDS-related mortality in British Columbia between 1981 and 2013

B. Yip, R. Hogg, J. Montaner, 2015 .

Retention in care and mortality trends among patients receiving comprehensive care for HIV infection: a retrospective cohort study.

B. Yip, J. Montaner, R. Barrios, 2019, CMAJ open.

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.

Julio S. G. Montaner, P. Harrigan, B. Yip, 2006, The Journal of infectious diseases.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

B. Yip, R. Hogg, J. Montaner, 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Validity of Self-Reported Adherence Among Injection Drug Users

Julio S. G. Montaner, B. Yip, R. Hogg, 2008, Journal of the International Association of Physicians in AIDS Care.

Reductions in all‐cause and cause‐specific mortality among HIV‐infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001–2012

B. Yip, R. Hogg, D. Moore, 2016, HIV medicine.

Is there a rural/urban gap in the quality of HIV care for treatment-naïve HIV-positive individuals initiating antiretroviral therapy in British Columbia?

B. Yip, R. Hogg, J. Montaner, 2017, AIDS care.

Superior virological response to boosted protease inhibitor‐based highly active antiretroviral therapy in an observational treatment programme

P. Harrigan, B. Yip, E. Wood, 2007, HIV medicine.

Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

P. Harrigan, B. Yip, R. Hogg, 2006, Antiviral Therapy.

Hospitalization Rates and Causes among Persons with HIV in the US and Canada, 2005-2015.

Richard D Moore, Jennifer S. Lee, Jeffrey N. Martin, 2020, The Journal of infectious diseases.

Performance of Immunologic Responses in Predicting Viral Load Suppression: Implications for Monitoring Patients in Resource-Limited Settings

B. Yip, R. Hogg, J. Montaner, 2006, Journal of acquired immune deficiency syndromes.

Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States.

B. Yip, R. Hogg, J. Montaner, 2002, AIDS.

Temporal trends in the discontinuation of first-line antiretroviral therapy.

B. Yip, R. Hogg, R. Harrigan, 2014, The Journal of antimicrobial chemotherapy.

Exploring Mitochondrial Nephrotoxicity as a Potential Mechanism of Kidney Dysfunction among HIV-Infected Patients on Highly Active Antiretroviral Therapy

P. Harrigan, B. Yip, R. Hogg, 2006, Antiviral therapy.

Mitochondrial Toxicity in the Era of HAART: Evaluating Venous Lactate and Peripheral Blood Mitochondrial DNA in HIV-Infected Patients Taking Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy

B. Yip, R. Hogg, J. Montaner, 2005, Journal of acquired immune deficiency syndromes.

703 Moore

B. Yip, R. Hogg, J. Montaner, 2006 .

Short communication Risks of non-accidental mortality by baseline CD4 + T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2006 .

Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2017, BMC Infectious Diseases.

Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study

B. Yip, R. Hogg, J. Montaner, 2015, PharmacoEconomics.

Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting

P. Harrigan, B. Yip, R. Hogg, 2014, PloS one.

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Evan Wood, P. Harrigan, B. Yip, 2003, AIDS.

Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 1998, AIDS.

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2005, The Journal of infectious diseases.

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

P. Harrigan, B. Yip, R. Hogg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy

Evan Wood, P. Harrigan, B. Yip, 2007, AIDS.

Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART

P. Harrigan, B. Yip, R. Hogg, 2006, PLoS medicine.

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up

B. Yip, R. Hogg, J. Montaner, 2002, AIDS.

The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time

B. Yip, R. Hogg, J. Montaner, 2009, Journal of acquired immune deficiency syndromes.

Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level

P. Harrigan, B. Yip, R. Hogg, 2010, Journal of acquired immune deficiency syndromes.

Nonadherence Increases the Risk of Hospitalization Among HIV-Infected Antiretroviral Naïve Patients Started on HAART

A. Levy, B. Yip, R. Hogg, 2008, Journal of the International Association of Physicians in AIDS Care.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2008, The Journal of infectious diseases.

Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort

B. Yip, R. Hogg, J. Montaner, 2006, AIDS.

Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.

B. Yip, R. Hogg, J. Montaner, 2006, The Journal of infectious diseases.

Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients

B. Yip, R. Hogg, J. Montaner, 2005, Canadian Medical Association Journal.

Why are Baseline HIV RNA Levels 100,000 Copies/mL or Greater Associated With Mortality After the Initiation of Antiretroviral Therapy?

P. Harrigan, B. Yip, R. Hogg, 2005, Journal of acquired immune deficiency syndromes.

Gender Differences in HIV-1 RNA Rebound Attributed to Incomplete Antiretroviral Adherence Among HIV-Infected Patients in a Population-Based Cohort

B. Yip, R. Hogg, J. Montaner, 2004, Journal of acquired immune deficiency syndromes.

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

A. Levy, P. Harrigan, B. Yip, 2004, The Journal of infectious diseases.

Adherence to Antiretroviral Therapy and Cd4 T-Cell Count Responses among HIV-Infected Injection Drug Users

B. Yip, R. Hogg, J. Montaner, 2004, Antiviral therapy.

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies

B. Yip, R. Hogg, J. Montaner, 2003, AIDS.

Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995–2000

A. Levy, B. Yip, R. Hogg, 2003, AIDS.

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Age, Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

Highly Active Antiretroviral Therapy: Physician Experience and Enhanced Adherence to Prescription Refill

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

B. Yip, R. Hogg, J. Montaner, 2002, Journal of acquired immune deficiency syndromes.

Safety and Efficacy of Once-Daily Nevirapine Dosing: A Multicohort Study

B. Yip, R. Hogg, J. Montaner, 2009, Antiviral therapy.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

P. Harrigan, B. Yip, R. Hogg, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Highly active antiretroviral therapy and survival in HIV-infected injection drug users.

B. Yip, R. Hogg, J. Montaner, 2008, JAMA.

Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada

P. Harrigan, B. Yip, R. Hogg, 2015, Antiviral therapy.

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

Evan Wood, Kate Shannon, Thomas Kerr, 2010, The Lancet.

Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 1998, PharmacoEconomics.

Elevated rates of antiretroviral treatment discontinuation among HIV-infected injection drug users: implications for drug policy and public health

Julio S. G. Montaner, B. Yip, R. Hogg, 2004 .

Total Lymphocyte Count as a Possible Surrogate of Cd4 Cell Count to Prioritize Eligibility for Antiretroviral Therapy among HIV-Infected Individuals in Resource-Limited Settings

B. Yip, R. Hogg, J. Montaner, 2002, Antiviral therapy.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

P. Harrigan, B. Yip, J. Montaner, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals.

P. Harrigan, B. Yip, R. Hogg, 2009, American journal of public health.

AssociationBetweenHIV-1RNALevelandCD4Cell CountAmongUntreatedHIV-InfectedIndividuals

P. Harrigan, B. Yip, R. Hogg, 2009 .

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use

Evan Wood, P. Harrigan, B. Yip, 2005, AIDS.

Decline in deaths from AIDS due to new antiretrovirals

B. Yip, R. Hogg, J. Montaner, 1997, The Lancet.

One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States

Sally S Bebawy, Richard D Moore, Jennifer S. Lee, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.

B. Yip, R. Hogg, J. Montaner, 2014, The Lancet. Infectious diseases.

Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy

James I Mullins, M. Jensen, J. Mullins, 2004, AIDS.

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

P. Harrigan, B. Yip, R. Hogg, 2001, AIDS.

Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration

J. Sterne, B. Yip, M. Gill, 2018, Journal of clinical medicine.

Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy

P. Harrigan, B. Yip, R. Hogg, 2012, PloS one.

Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

P. Harrigan, B. Yip, R. Hogg, 2016, BMC Infectious Diseases.

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients

P. Harrigan, B. Yip, R. Hogg, 2007, AIDS.

Physicians’ patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting

B. Yip, R. Hogg, J. Montaner, 2019, BMJ Open.

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function

B. Yip, R. Hogg, J. Montaner, 2016, Journal of the International AIDS Society.

The causal effect of opioid substitution treatment on HAART medication refill adherence

B. Yip, J. Montaner, E. Wood, 2015, AIDS.

Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV—Positive Adult Men and Women

B. Yip, R. Hogg, J. Montaner, 1998, PharmacoEconomics (Auckland).

Letters to the Editor

B. Yip, R. Hogg, J. Montaner, 1998 .

Adverse drug reactions to integrase strand transfer inhibitors

B. Yip, J. Montaner, Lu Wang, 2018, AIDS.

CD4 Cell Count Response to Nonnucleoside Reverse Transcriptase Inhibitor‐or Protease Inhibitor‐Based Highly Active Antiretroviral Therapy in an Observational Cohort Study

B. Yip, R. Hogg, J. Montaner, 2003, Journal of acquired immune deficiency syndromes.

Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response

B. Yip, R. Hogg, J. Montaner, 2006, AIDS.

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.

P. Harrigan, B. Yip, R. Hogg, 2003, The Journal of infectious diseases.

HIV-1 Disease Progression During Highly Active Antiretroviral Therapy: An Application Using Population-Level Data in British Columbia: 1996–2011

B. Yip, R. Hogg, J. Montaner, 2013, Journal of acquired immune deficiency syndromes.

Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

P. Harrigan, B. Yip, J. Joy, 2019, Open forum infectious diseases.

Emergent drug resistance with integrase strand transfer inhibitor-based regimens

P. Harrigan, B. Yip, J. Montaner, 2017, AIDS.

Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.

B. Yip, R. Hogg, J. Montaner, 2005, The Journal of infectious diseases.

Cohort profile: the Canadian Observational Cohort collaboration.

Curtis Cooper, Marek Smieja, Julio Montaner, 2011, International journal of epidemiology.

Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay

B. Yip, J. Montaner, B. Wynhoven, 2012, PloS one.

Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy

B. Yip, R. Hogg, J. Montaner, 2000, AIDS.

Predicting hospitalization among HIV-infected antiretroviral naïve patients starting HAART: Determining clinical markers and exploring social pathways

A. Levy, B. Yip, R. Hogg, 2008, AIDS Care.

CD4+ T-Cell Gain With Nonnucleoside or Protease Inhibitors: Convenience May Not Always Be The Most Convenient:Reply

P. Harrigan, B. Yip, R. Hogg, 2004 .

The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study

B. Yip, R. Hogg, J. Montaner, 2018, BMC Health Services Research.

Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.

P. Harrigan, B. Yip, R. Hogg, 2008, AIDS (London).

The adherence gap: a longitudinal examination of men's and women's antiretroviral therapy adherence in British Columbia, 2000–2014

B. Yip, R. Hogg, J. Montaner, 2017, AIDS.

The gender gap: a longitudinal examination of men's and women's art adherence in british columbia, 2000-2014.

B. Yip, R. Hogg, J. Montaner, 2017, AIDS.

Epidemiology of antiretroviral multiclass resistance.

P. Harrigan, B. Yip, R. Hogg, 2010, American journal of epidemiology.

Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence

P. Harrigan, B. Yip, R. Hogg, 2004, AIDS.

Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.

Richard D Moore, Jennifer S. Lee, J. Margolick, 2019, The lancet. HIV.

Highly active antiretroviral therapy and survival in HIV-infected injection drug users.

B. Yip, R. Hogg, J. Montaner, 2008, JAMA.

Factors Predictive of 30-Day Postoperative Mortality in HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy

S. Wiseman, B. Yip, R. Hogg, 2012, Annals of surgery.

The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS

B. Yip, R. Hogg, J. Montaner, 2000 .

Barriers to use of free antiretroviral therapy in injection drug users.

B. Yip, R. Hogg, J. Montaner, 1998, JAMA.

B. Yip, R. Hogg, J. Montaner, 2004, Quality of Life Research.

CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018

Richard D Moore, Jennifer S. Lee, Jeffrey N. Martin, 2020, Clinical Infectious Diseases.

Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Risks of Non-Accidental Mortality by Baseline CD4+ T-Cell Strata in Hepatitis-C-Positive and -Negative Individuals Initiating Highly Active Antiretroviral Therapy

B. Yip, R. Hogg, J. Montaner, 2006, Antiviral therapy.

Use of metabolic drugs and fish oil in HIV‐positive patients with metabolic complications and associations with dyslipidaemia and treatment targets

B. Yip, R. Hogg, G. Bondy, 2007, HIV medicine.

Highly active antiretroviral therapy and survival in HIV-infected injection drug users.

B. Yip, R. Hogg, J. Montaner, 2008, JAMA.

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

B. Yip, R. Hogg, J. Montaner, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.